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This data article contains data related to the research article entitled,
“A proteomic analysis of p53-independent induction of apoptosis by
bortezomib in 4T1 breast cancer cell line” by Yerlikaya et al. [1]. The
research article presented 2-DE and nLC-MS/MS based proteomic
analysis of proteasome inhibitor bortezomib-induced changes in the
expression of cellular proteins. The report showed that GRP78 and
TCEB2 were over-expressed in response to treatment with bortezo-
mib for 24 h. In addition, the report demonstrated that Hsp70, the
26S proteasome non-ATPase regulatory subunit 14 and sequestosome
1 were increased at least 2 fold in p53-deﬁcient 4T1 cells. The data
here show for the ﬁrst time the increased expressions of Card10, Dffb,
Traf3 and Trp53bp2 in response to inhibition of the 26S proteasome.
The information presented here also shows that both Traf1 and Xiap
(a member of IAPs) are also downregulated simultaneously upon
proteasomal inhibition. The increases in the level of Card10 and
Trp53bp2 proteins were veriﬁed byWestern blot analysis in response
to varying concentrations of bortezomib for 24 h.
& 2014 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).ier Inc. This is an open access article under the CC BY license
/j.jprot.2014.09.010
erlikaya).
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Real-time PCR measurem
24 h, followed by RNA i
performed using RT2 SYB
of genes upregulated or
Gene Symbol
Upregulated genes
Atf5
Bag3
Bcl2a1a
Card10
Cd40
Dffb
Gadd45a
Tnfrsf10b
Traf3
Trp53bp2
Hsp90ab1
Downregulated genes
Bcl2l1
Fadd
Traf1
XiapSubject area Medicine, BiologyMore speciﬁc subject
areaMolecular Biology, Cancer BiologyType of data Table, ﬁgure
How data was
acquiredReal-Time PCR, Western blotting systemData format Analyzed
Experimental factors p53-null mouse 4T1 cell line were treated with isotonic solution or varying doses of bortezomib.
Experimental
featuresTotal RNA is isolated and then converted to cDNA. The cDNA samples quantiﬁed with Roche Light Cycler
480 platform. The Western blots were carried out with Amersham ECL Western blotting kit.Data source location Kütahya, Turkey
Data accessibility The data are supplied with this article.The value of the data Proteasome inhibition regulates the expression of Card10, Dffb, Traf3, Trp53bp2, Bcl2-like 1, Fadd,
Traf1 and Xiap proteins in p53-null 4T1 breast carcinoma cells. These proteins have critical roles in cellular homeostasis and cancer cell survival [2,3,4].
 The data are useful for understanding the role of proteasome in cancer development.
 The data are also valuable for elucidating the mechanism of regulation of these genes under the
conditions of proteasomal inhibition.
1. Data, experimental design, materials and methods
The data shown here report the changes in the expression levels of apoptosis-related genes in p53-
null 4T1 mouse breast carcinoma cell lines [5,6]. The changes in the expression of apoptosis-relatedents. Mouse 4T1 cells were seeded in 6015 mm2 dishes and treated with 100 nM bortezomib for
solation using RNeasy mini kit and QIAcube instrument. The quantitative PCR measurements were
R Green Mastermix and Roche Light Cylcer 480 platform. The average ΔCT values and the fold changes
downregulated are indicated in the table. The data are the average of two independent experiments.
Description Avg ΔCT Fold change
Control Bortezomib
Activating transcription factor 5 7.1075 5.8725 2.3538
Bcl2-associated athanogene 3 4.9875 3.0025 3.9586
B-cell leukemia/lymphoma 2 related protein A1a 16.4775 14.2725 4.6107
Caspase recruitment domain family, member 10 4.1475 1.7425 5.2964
CD40 antigen 9.8975 8.1525 3.3519
DNA fragmentation factor, beta subunit 10.0775 8.5125 2.9588
Growth arrest and DNA-damage-inducible 45 alpha 5.0075 3.5225 2.7992
Tumor necrosis factor receptor superfamily, member 10b 4.8875 3.7625 2.181
Tnf receptor-associated factor 3 5.7975 4.5725 2.3376
Transformation related protein 53 binding protein 2 5.8075 4.7425 2.0922
Heat shock protein 90 alpha (cytosolic), class B member 1 1.2725 2.7675 2.8186
Bcl2-like 1 4.0875 5.4325 0.3937
Fas (TNFRSF6)-associated via death domain 6.8175 7.9925 0.4429
Tnf receptor-associated factor 1 5.3375 6.7425 0.3776
X-linked inhibitor of apoptosis 5.9275 7.0425 0.4617
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or PS-341) for 24 h. Eleven apoptosis-related genes were upregulated in response to 100 nM
bortezomib-treatment. Additionally, Bcl2l1, Fadd, Traf1 and Xiap genes are found to be downregulated
in a p53-independent manner in 4T1 cells.
Real-Time PCR – Mouse 4T1 cell lines were seeded in 6015 mm2 petri dishes and treated with
100 nM bortezomib at the logarithmic phase of the growth for 24 h. Afterwards, RNA was isolated
using RNeasy mini kit and QIAcube instrument according to the manufacturer's protocolFig. 1. (A) Examination of Card10 and Trp53bp2 proteins by Western blotting. 4T1 cells were treated with various
concentrations of bortezomib (10, 50, 100 and 200 nM) for 24 h. And then the levels of Card10 (upper panel) and Trp53bp2
(middle panel) were analyzed by rabbit anti-Card10 (1:500 dilution) or mouse anti-Trp53bp2 (1:500 dilution) antibodies,
respectively. The lower panel shows the level of loading control β-actin. The result is a representative of 2 independent
experiments, each run in duplicates. (B) Quantitation of Card10 and Trp53bp2 protein bands seen in Panel A by GelQuantNET.
The data are graphed by Graphpad Prism 3.03 program. The control level is set to 1.
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amount of total RNA (1 μg from each sample), and then cDNA was synthesized for each sample
using RT2 First Strand kit (SABioscience, Frederick, MD, USA). Equal amounts of cDNAs from
control and treated samples were mixed with RT2 SYBR Green Mastermix and 25 μl PCR
component mix was added to each well of mouse RT2 proﬁler apoptosis PCR array using a 12-
channel pipettor. After tightly sealing the RT2 PCR array with optical adhesive ﬁlm, the absolute
quantiﬁcation was performed with Roche Light Cycler 480 platform using 1 cycle of hotstart
(10 min at 95 1C) and 45 cycles of ampliﬁcation (15 s at 95 1C and 1 min at 60 1C). Data were
normalized using housekeeping genes (beta-actin, beta-2 microglobulin, glyceraldehyde-3-
phosphate dehydrogenase and beta-glucuronidase) and analyzed by comparing 2–ΔCT.
The data presented here shows that inhibition of the 26S proteasome causes signiﬁcant changes
in the expression of Card10, Dffb, Traf3 and Trp53bp2 genes. In addition, four genes were found
consistently downregulated in response to treatment with bortezomib for 24 h. The genes
downregulated were Bcl2-like 1, Fas (TNFRSF6)-associated via death domain, Tnf receptor-
associated factor 1 and X-linked inhibitor of apoptosis proteins (Table 1).
Western blotting – The ECLWestern blotting kit was used according to manufacturer procedure (GE
Healthcare, Stockholm, Sweden). A total of 50 μg protein from each sample was separated on a 12%
SDS-PAGE. Afterwards, proteins were transferred to PVDF membranes at 70 V for 2 h. After the
transfer, the PVDF membranes were washed brieﬂy with methanol and left for drying for 15 min to
enhance the protein binding. The PVDF membranes were again reactivated by methanol. The
membranes were blocked by 5% non-fat dried milk in TBS-T. The membranes were then incubated
with anti-Card10 (1:500) and anti-Trp53BP2 (1:500) for 1 h. For loading control, the membranes were
probed with anti-β-actin antibody (1:5000) in TBS-T for 1 h. The membranes were then incubated
with HRP-conjugated anti-rabbit secondary antibody (1:5000 dilution) in TBS-T for 1 h.
The Western blot analysis results indicated that the increases in Card10 (Fig. 1A, upper panel) and
Trp53bp2 (Fig. 1A, middle panel) proteins were corroborated in response to proteasomal inhibition by
various concentrations of bortezomib for 24 h. The examination of β-actin level (Fig. 1A, lower panel)
showed that the changes in the protein levels of Card10 and Trp53bp2 were not simply due to higher
protein loading. As can be seen in Fig. 1B, when the cells were treated with different doses of
bortezomib, a threshold-dependent increase in Card10 protein was clearly observed. With 10 nM,
50 nM, 100 nM and 200 nM, 1.84 fold, 2.31 fold, 2.26 fold and 3.78 fold increases were detected,
respectively. On the other hand, the increase in the level of Trp53bp2 protein was observed with only
higher doses of bortezomib (i.e., 100 nM and 200 nM) (Fig. 1B).
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